PTGX · Protagonist Therapeutics, Inc · Executive Compensation
$140.06
+0.87 (+0.63%)
At close · Oct 2
Return incl. dividend (before tax)
Market Cap
$9.18B
Shares
64.71M
Volume · Oct 2
760.3K
Avg daily vol (3M)
634.39K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Dinesh Patel | President and Chief Executive Officer | $12,871,506 |
| Dinesh V. Patel | President and Chief Executive Officer | $12,871,506 |
| Arturo Molina | M.D., M.S., F.A.C.P. Chief Medical Officer | $4,095,230 |
| Asif Ali | EVP, Chief Financial Officer | $3,257,489 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Dinesh Patel | President and Chief Executive Officer | $9,473,819 |
| Dinesh V. Patel | President and Chief Executive Officer | $9,473,819 |
| Arturo Molina | M.D., M.S., F.A.C.P. Chief Medical Officer | $3,464,201 |
| Asif Ali | EVP, Chief Financial Officer | $2,810,873 |
| Suneel Gupta | Ph.D. Chief Development Officer | $2,735,526 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Dinesh V. Patel | President and Chief Executive Officer | $7,067,572 |
| Dinesh Patel | President and Chief Executive Officer | $7,067,572 |
| Suneel Gupta | Ph.D. Chief Development Officer | $2,216,189 |
| Asif Ali | EVP, Chief Financial Officer | $1,402,215 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Dinesh V. Patel | President and Chief Executive Officer | $5,993,238 |
| Dinesh Patel | President and Chief Executive Officer | $5,993,238 |
| Suneel Gupta | Ph.D. Chief Development Officer | $2,684,804 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Dinesh V. Patel | President and Chief Executive Officer | $5,544,733 |
| Dinesh Patel | President and Chief Executive Officer | $5,544,733 |
| Suneel Gupta | Chief Development Officer | $2,375,110 |
| David Y. Liu | Chief Research and Development Strategy Officer | $2,070,827 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Dinesh Patel | President and Chief Executive Officer | $2,225,622 |
| Dinesh V. Patel | President and Chief Executive Officer | $2,225,622 |
| Suneel Gupta | Chief Development Officer | $1,108,270 |
| David Y. Liu | Chief Research and Development Strategy Officer | $1,071,849 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Dinesh Patel | President and Chief Executive Officer | $1,948,344 |
| Dinesh V. Patel | President and Chief Executive Officer | $1,948,344 |
| Suneel Gupta | Chief Development Officer | $1,331,737 |
| David Y. Liu | Chief Scientific Officer and Head of Discovery and Pre-Clinical Development | $1,199,598 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Dinesh V. Patel | President and Chief Executive Officer | $3,721,511 |
| Dinesh Patel | President and Chief Executive Officer | $3,721,511 |
| David Y. Liu | Chief Scientific Officer and Head of Research and Development | $1,618,355 |
| Suneel Gupta | Chief Development Officer | $98,105 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Lewis T. “Rusty” Williams | Class I director | Appointed | 2026-06-18 |
| Dinesh V. Patel | Class I director | Appointed | 2026-06-18 |
| Sarah A. O'Dowd | member of the Audit Committee of the Board | Appointed | 2024-09-20 |
| Daniel N. Swisher Jr. | member of the Board of Directors | Resigned | 2024-09-20 |
| Daniel N. Swisher, Jr. | Class I director | Appointed | 2023-10-30 |